Apogee Biotechnology Corporation, founded in 2001 by Charles D. Smith, Ph. D., is a privately held company based at the Hershey Center for Applied Research in Hershey, Pennsylvania.

Specializing in the development of orally available, small molecules, Apogee focuses on treating cancer and inflammatory diseases. Their sphingosine kinase inhibitor program targets solid tumors and chronic inflammatory diseases, as well as indications of damaging acute inflammation. Within their product pipeline, they have a clinical lead compound called ABC294640 (opaganib), which is a small molecule inhibitor of sphingosine kinase.

This compound has shown efficacy in the treatment of various cancer types and inflammatory diseases, including COVID-19. In addition, ABC294640 has demonstrated synergistic effects when combined with standard-of-care drugs in animal models, making it a promising add-on therapy for future clinical trials. Apogee Biotechnology Corporation is at the forefront of developing innovative solutions to improve patient outcomes in the field of oncology and inflammation